Pfizer (PFE)

Operating Expenses

$29.45B

TTM · Period ending: · USD

PFE logo

PFE Operating Expenses

Latest reported$29.45B
PFE TTM Operating Expenses (-$3.52B → $29.45B)
High-resolution chart · PNG

PFE operating expenses history

Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.

Pfizer Operating Expenses — Trailing twelve months (TTM) (USD)
Period endingOperating Expenses (USD)
29,453,000,000
29,062,000,000
28,577,000,000
27,223,000,000
24,094,000,000
24,613,000,000
25,349,000,000
25,349,000,000
25,440,000,000
25,137,000,000
25,049,000,000
25,848,000,000
25,904,000,000
25,572,000,000
24,541,000,000
26,379,000,000
25,859,000,000
25,196,000,000
25,083,000,000
22,225,000,000
21,716,000,000
21,321,000,000
20,817,000,000
20,823,000,000
21,419,000,000
22,073,000,000
22,895,000,000
22,293,000,000
22,252,000,000
22,243,000,000
22,350,000,000
22,758,000,000
22,610,000,000
22,485,000,000
22,353,000,000
22,419,000,000
22,499,000,000
23,488,000,000
24,610,000,000
26,086,000,000
26,607,000,000
26,419,000,000
26,226,000,000
25,989,000,000
26,390,000,000
26,678,000,000
26,529,000,000
25,476,000,000
25,285,000,000
25,266,000,000
26,105,000,000
27,206,000,000
28,123,000,000
28,829,000,000
29,835,000,000
31,032,000,000
32,182,000,000
33,820,000,000
34,992,000,000
36,529,000,000
38,659,000,000
38,726,000,000
38,414,000,000
36,668,000,000
32,000,000,000
29,048,000,000
25,665,000,000
23,057,000,000
23,418,000,000
24,190,000,000
25,150,000,000
26,252,000,000
26,764,000,000
27,064,000,000
26,843,000,000
26,963,000,000
26,873,000,000
26,527,000,000
26,912,000,000
26,732,000,000
26,831,000,000
27,345,000,000
27,850,000,000
28,113,000,000
28,330,000,000
28,277,000,000
27,128,000,000
27,256,000,000
27,021,000,000
26,189,000,000
24,573,000,000
20,119,000,000
17,800,000,000
15,982,000,000
16,051,000,000
17,289,000,000
16,958,000,000
16,651,000,000
16,249,000,000
16,064,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.